EnsiliTech
Overview
EnsiliTech is a biotechnology company based in Bristol, United Kingdom, founded in 2022 by Dr. Asel Sartbaeva, Dr. Stephen Wells, Dr. Aswin Doekhie, and Dr. Matt Slade. The company has developed a patented technology called Ensilication, which stabilizes biopharmaceuticals at higher temperatures, making cold chain logistics unnecessary. EnsiliTech has recently raised €5.2 million in Seed funding to further its mission of reducing biopharmaceutical supply chain costs and enhancing global medicine access.
Recent Developments
- August 2025: EnsiliTech announced the closure of a €5.2 million Seed funding round led by Eos Advisory. This investment aims to support the company's innovative Ensilication technology, which allows vaccines and biopharmaceuticals to remain stable at temperatures up to 50°C.
- The funding will drive validation studies necessary for integrating Ensilication technology into standard pharmaceutical manufacturing processes and expand the company’s team and infrastructure.
- EnsiliTech won several accolades, including StartUp of the Year South West 2025, recognizing its groundbreaking preservation technology.
- HERmesa, a group dedicated to investing in women-led businesses, invested in EnsiliTech, emphasizing the startup's female-led leadership team.
- Dr. Asel Sartbaeva, CEO of EnsiliTech, was named ‘Founder of the Year’ at The Sparkies Awards 2025.
- The company's leadership and R&D teams are predominantly female, aligning with its commitment to diversity and inclusion in the tech industry.
- EnsiliTech has been featured in multiple press releases highlighting its mission to make life-saving medicines more accessible by eliminating refrigeration needs, significantly reducing pharmaceutical industry losses attributed to cold chain failures.
- The company was also showcased as a breakthrough technology innovator by the Royal Society of Chemistry, validating its scientific approach and potential.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2022 |
| Headquarters | Bristol, UK |
| Founders | Dr. Asel Sartbaeva, Dr. Stephen Wells, Dr. Aswin Doekhie, Dr. Matt Slade |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Eos Advisory, Calculus Capital, Empirical Ventures, HERmesa |
| Industry | Biotechnology |
| Number of Employees | Not publicly disclosed |
Early History
EnsiliTech was co-founded by Dr. Asel Sartbaeva and her team in Bristol, UK, in 2022. The company's origins trace back to research conducted at the University of Bath, focusing on stabilizing vaccines and other biologics without the need for refrigeration. This innovation was driven by Dr. Sartbaeva’s personal experiences and the industry's ever-present issue of cold-chain dependency, especially in regions lacking reliable refrigeration infrastructure. In December 2022, EnsiliTech secured its first oversubscribed pre-seed investment of £1.2 million, propelling the nascent company into the biotech landscape with a commitment to scalability and sustainability.
Company Profile and Achievements
EnsiliTech employs a unique business model centered around its proprietary Ensilication technology. This innovation encapsulates biologics such as vaccines and antibodies in a protective silica layer, allowing them to remain stable even in challenging environmental conditions. Key milestones include:
- 2022: Founded and completed an initial investment round.
- 2023: Raised €1.3 million in a follow-up funding round, validating early investor confidence.
- 2024: Garnered recognition for technological innovation by being shortlisted for various tech and science awards.
- 2025: Significant Seed funding secured, coupled with multiple industry awards, reinforcing EnsiliTech's market position and innovation capabilities.
- The technology holds significant promise for mRNA therapies, facilitating vast improvements in vaccine and treatment accessibility.
Current Operations and Market Position
EnsiliTech currently focuses on scaling its Ensilication technology for wider pharmaceutical applications. By eliminating dependence on traditional cold-chain logistics, the company addresses a €30 billion industry issue, allowing for cost reductions and improved product efficacy. EnsiliTech positions itself as a transformative force within the biotech sector, actively seeking partnerships to expand its technology’s application in both human and animal health markets. The start-up boasts over ten different investors, underscoring a robust market positioning and clear potential for leadership in biologics thermostabilisation.
Conclusion
EnsiliTech is set to make significant impacts on the biopharmaceutical industry by introducing sustainable, efficient, and scalable solutions to cold-chain dependencies. The company's Ensilication technology presents a paradigm shift in vaccine and biologics transport and storage, making health solutions more accessible, especially in under-resourced regions. With continued growth and innovation, EnsiliTech is poised to expand its influence, secure more partnerships, and set new standards in pharmaceutical distribution systems, reflecting a promising trajectory in transforming global health logistics.